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Parotid tumors account for about 3% of all head and neck tumors. Of parotid tumors, 80%–85% are benign, most of which are pleomorphic adenoma (PA) and Warthin tumor (WT) (1). The preoperative imaging examinations of parotid tumors are im-
portant for differentiation between benign and malignant tumors as well as localization 
of intraparotid facial nerve and include ultrasonography, computed tomography (CT), and 
magnetic resonance imaging (MRI) (2–12). However, the efficacy of preoperative imaging is 
still controversial for differentiating the tumors of various histologic types because of wide 
range of overlap between the imaging findings.
Two-phase CT is an abbreviated form of dynamic contrast-enhanced CT technique, which 
can provide functional analysis through the essential information on perfusion of the lesion 
(2, 13). As described by Choi et al. (2), this technique is well known for differentiation of WTs 
from other tumors of the parotid gland, including PAs and malignant tumors. They reported 
early enhancement and washout of contrast material as the characteristic enhancement 
pattern of WTs. Using immunohistochemical staining, Woo et al. (13) showed that abundant 
blood vessels and extensive capillary networks as well as lack of complete vessel wall cov-
erage form the pathologic basis for the enhancement pattern of WTs at two-phase CT. They 
also reported significantly different enhancement pattern in WTs compared with a group of 
benign tumors other than PAs. 
In our experience, basal cell adenomas (BCAs) and myoepitheliomas (MEs), both of which 
are unusual benign tumors of the salivary gland, frequently demonstrate an enhancement 
PURPOSE 
Early enhancement and a washout pattern are reported to be the characteristic imaging features 
of Warthin tumor (WT). The purpose of this study was to evaluate the enhancement patterns of 
basal cell adenoma (BCA) and myoepithelioma (ME) of the parotid gland on two-phase comput-
ed tomography (CT), compared with WT.
METHODS
We retrospectively evaluated two-phase CT examinations of histologically proven 19 BCAs, 12 
MEs, and 23 WTs of the parotid gland. In all patients, CT scans were obtained at early and de-
layed phases with scanning delays of 40 and 180 s, respectively. We measured the attenuation 
values on each phase of CT scans and calculated washout attenuation and relative percentage 
enhancement washout ratio. From the data acquired, we statistically compared the enhancing 
characteristics among three tumor groups. 
RESULTS
Based on the results of washout attenuation and relative percentage enhancement washout ra-
tio, 15 (79%) of 19 BCAs, 9 (75%) of 12 MEs, and 23 (100%) of 23 WTs demonstrated a washout 
pattern of enhancement on two-phase CT scans. Despite variations of the individual tumors, 
both parameters revealed no significant difference among three tumor groups.
CONCLUSION
BCAs and MEs of the parotid gland frequently show early enhancement and a washout pattern 
on two-phase CT, which can be indistinguishable from WTs in the majority of cases.
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pattern similar to WTs at two-phase CT 
scanning. Although several studies have 
reported the general imaging features of 
BCAs (14–17) and MEs (18, 19), only a few 
have dealt with their enhancement pattern 
on dynamic CT and MRI examinations in-
cluding two-phase CT (16, 20–22). Further-
more, to our knowledge, there have been 
no comparative studies on the enhance-
ment pattern between these tumors and 
WTs on two-phase CT. The purpose of this 
study was to investigate the differences, if 
any, in the enhancement pattern among 
BCAs, MEs, and WTs on two-phase CT.
Methods
Study subjects
Our study was approved by our institu-
tional review board (IRB file no. SMC 2018-
07-127) and informed consent was waived 
in accordance with the requirements of 
a retrospective study. Between 2005 and 
2014, a search of medical records from an 
electronic database in our institution iden-
tified 26 patients with BCA and 15 patients 
with MEs of the parotid gland. After exclu-
sion for absence of two-phase CT scan-
ning, we included 19 patients (5 men, 14 
women; mean age, 62 years; range, 39–75 
years) with BCA and 10 patients (3 men, 7 
women; mean age, 56 years; range, 21–74 
years) with ME. All patients with BCA and 
8 of 10 patients with ME had single lesion, 
while two patients with ME, both of whom 
had a history of previous surgery, had two 
lesions on the same side of the operated 
parotid gland. For controls, consecutive 
20 patients (19 men, 1 woman; mean age, 
55 years; range, 47–71 years) with WT who 
underwent two-phase CT examination in 
2013 were collected from the database of 
the Radiology Department of our hospital. 
Three of the 20 patients with WT had two 
lesions on the same side (n=1) or on both 
sides (n=2) of the parotid gland. Finally, 
we included 19 BCAs, 12 MEs, and 23 WTs, 
which formed the basis of this study. The 
diagnosis was confirmed histologically by 
surgery in all lesions including multiple tu-
mors in patients with ME and WT.
 
CT scanning and analysis
For all patients, two-phase CT scans were 
obtained in the axial plane from thoracic in-
let to inferior orbital ridge by using various 
models of a multidetector-row CT scanner 
with 2.5 to 3.75 mm section thickness. After 
the intravenous administration of 90 mL of 
iodinated contrast material into an antecu-
bital vein at a rate of 3 mL/s with a power 
injector, early and delayed phase scans 
were obtained with scanning delays of 40 
and 180 s, respectively. Based on the dose 
report generated by CT scanner, mean vol-
umetric CT dose index (CTDIvol) was 28.2 
mGy per phase of CT scanning (range, 10.9–
37.5 mGy) and mean dose-length product 
(DLP) was 792 mGy·cm (range, 206–1559 
mGy·cm). 
CT scans were interpreted by a dedicat-
ed head and neck neuroradiologist and 
a general neuroradiologist in consensus, 
who have been practicing in the field for 26 
years and 5 years, respectively. They were 
blinded to the pathology results. First, we 
recorded the general morphologic charac-
teristics of the tumor, such as the size (at its 
greatest diameter), location (superficial or 
deep lobe), margin (well-defined, microlo-
bulated, or indistinct), and presence of the 
cystic change or calcification. Second, for 
quantitative analysis of the enhancing char-
acteristics, we measured CT attenuation 
values (in HU) on early (40 s) and delayed 
(180 s) CT scans by placing the largest pos-
sible circular region of interest (2.6–124.5 
mm2) within the solid portion of the lesion 
with caution to avoid the cystic area. From 
these, as described by Kamiyama et al. (23), 
we calculated the following diagnostic pa-
rameters in each tumor: washout attenua-
tion (AWO) as AWO = AE – AD, where AE is atten-
uation value on early-phase CT scan and 
AD is attenuation value on delayed-phase 
CT scan; and relative percentage enhance-
ment washout ratio (RPEWR) as RPEWR (%) 
= (AWO / AE) × 100. From the data acquired, 
we compared the enhancing characteris-
tics on two-phase CT between each tumor 
group. We defined the washout enhance-
ment pattern as AE > AD. When AE < AD, it 
was defined as the gradual enhancement 
pattern.
Statistical analysis
The general morphologic features 
among three groups of tumor were com-
pared using Fisher exact test. The differenc-
es in mean ± SD values of tumor size, AE, AD, 
AWO, and RPEWR among three tumor groups 
were statistically evaluated by the analysis 
of variance test with the Tukey test as a post 
hoc test. Statistical analysis was performed 
by using the PASW software version 18.0 
(SPSS Inc.) and P < 0.05 was considered sta-
tistically significant.
Results
The general morphologic characteris-
tics of the three different tumor groups 
are summarized in Table 1. No statistically 
significant differences were found among 
the three tumor groups with regard to the 
size, location, margin, cystic change, and 
calcification. Among 19 BCAs, 12 MEs, and 
23 WTs, the mean size of the tumors was 
greatest for WT (2.8±0.89 cm), followed 
by BCA (2.4±1.15 cm) and ME (2.3±0.86 
cm). The superficial lobe was the pre-
dominant location of all three tumors: 
15 BCAs (78.9%), 10 MEs (83.3%), and 18 
WTs (78.3%) were located in the superfi-
cial lobe. Most tumors had a well-defined 
margin, seen in 18 BCAs (94.7%), 11 MEs 
(66.7%), and 22 WTs (95.7%). The cys-
tic change was demonstrated in 9 BCAs 
(47.4%), 6 MEs (50%), and 7 WTs (30.4%). 
Calcification was infrequent for all three 
tumors, seen in two BCAs (10.5%), one ME 
(8.3%), and one WT (4.3%). 
Results of the various CT parameters for 
the three tumors and their statistical com-
parisons are summarized in Tables 2 and 3. 
ME showed greater mean values for both 
AE (141.0±38.4) and AD (101.7±18.2) than 
BCA (114.6±39.3 and 83.5±24.6, respec-
tively) and WT (103.4±20.2 and 70.2±11.8, 
respectively). Statistically significant dif-
ference was found between ME and WT 
for both parameters (P = 0.02 for AE and 
P < 0.001 for AD). There was no statistical-
ly significant difference in AE and AD be-
tween BCA and WT (P = 0.61 for AE and P = 
0.12 for AD) and between BCA and ME (P = 
0.21 for AE and P = 0.07 for AD). Fig. 1 shows 
schematic drawings of the enhancement 
pattern of the three tumor groups.
Main points
• Warthin tumors are well-known for the char-
acteristic washout of contrast material at 
two-phase CT scanning, an abbreviated form 
of dynamic contrast-enhanced CT technique 
that can provide functional analysis through 
the essential information on perfusion of the 
lesion.
• Although rare, basal cell adenomas and myo-
epitheliomas also often demonstrate an en-
hancement pattern that is hard to differenti-
ate from that of Warthin tumors at two-phase 
CT.
• The washout pattern of enhancement seen 
in these tumors seems to reflect the promi-
nent vasculature within the solid component 
of the tumors histologically.
Most tumors in each group demonstrat-
ed a washout pattern of enhancement, 
as based on the results of AWO and RPEWR 
(Figs. 2–4) and included 15 (79%) of 19 BCAs 
(79%), 9 of 12 MEs (75%), and 23 of 23 WTs 
(100%). The remaining four BCAs (21%) 
and three MEs (25%) showed a gradual en-
hancement pattern. As for AWO, although ME 
showed the greater mean value (39.3±35.8) 
than BCA (31.2±37.8) and WT (33.2±15.7), 
there was no statistically significant differ-
ence among three tumor groups (P = 0.75). 
Likewise, although WT (31.2±9.8) showed 
the greater mean RPEWR value than ME 
(22.5±24.9) and BCA (18.4±40.0), no sta-
tistically significant difference was found 
among the three types of tumor (P = 0.31). 
Discussion 
BCAs and MEs are uncommon benign 
tumors of the salivary gland, both of which 
were accepted as a histologically distinct 
entity since 1991 by the World Health Orga-
nization. They comprise 1%–2% and 1.5% 
of all salivary gland epithelial tumors, re-
spectively, and predominantly occur in the 
parotid gland (15–17, 19, 21). Histologically, 
BCAs are characterized by a monomorphic 
population of basaloid cells sharply delin-
eated from the stroma by basement mem-
brane. The lack of myxochondroid stroma, 
myoepithelial cells, and mesenchymal 
mucin within the tumors helps distinguish 
BCAs from PAs (15–17). Four histologic sub-
types are recognized according to cellular 
growth patterns, including solid, tubular, 
trabecular, and membranous, with the solid 
subtype being the most frequent form and 
the membranous subtype having a high re-
currence rate (14, 16, 21). In contrast, MEs 
are composed almost exclusively of sheets, 
islands, or cords of cells with myoepithelial 
differentiation with spindle, plasmacytoid, 
epithelioid, or clear cytoplasmic features 
(18, 19, 24). Surgical excision is the treat-
ment of choice for both tumors.
In this study, both BCAs and MEs most 
frequently demonstrated rapid enhance-
ment and a washout pattern on two-phase 
CT scans, which was reported to be charac-
teristic of WTs (2, 13). Based on the results 
of AWO and RPEWR in our series, BCAs, MEs, 
and WTs showed a washout pattern of 
enhancement in 79%, 75%, and 100%, re-
spectively. Compared to AWO which simply 
represents the difference of the attenua-
tion values between AE and AD, the RPEWR 
is more objective, in that it represents the 
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Table 1. General morphologic tumor characteristics on CT
Basal cell adenoma Myoepithelioma Warthin tumor P
No. of cases 19 12 23
Size (cm), mean±SD 2.4±1.15 (0.9–4.3) 2.3±0.86 (1.1–3.6) 2.8±0.89 (1.8–4.5) 0.83
Location, n (%) 0.94
Superficial lobe 15 (78.9) 10 (83.3) 18 (78.3)
Deep lobe 4 (21.1) 2 (16.7) 5 (21.7)
Margin, n (%) 0.12
Well-defined 18 (94.7) 8 (66.7) 22 (95.7)
Microlobulated 1 (5.3) 3 (25) 1 (4.3)
Ill-defined 0 (0) 1 (8.3) 0 (0)
Cystic change, n (%) 0.26
Yes 9 (47.4) 6 (50) 7 (30.4)
No 10 (52.6) 6 (50) 16 (69.6)
Calcification, n (%) 0.75
Yes 2 (10.5) 1 (8.3) 1 (4.3)
No 17 (89.5) 11 (91.7) 22 (95.7)
SD, standard deviation.
Table 2. Results of CT parameters
Basal cell adenoma Myoepithelioma Warthin tumor P
AE 114.6±39.3 (33.3–173.5) 141.0±38.4 (67.6–187.1) 103.4±20.2 (68–154.6) 0.008
AD 83.5±24.6 (21.9–139.1) 101.7±18.2 (76.3–128) 70.2±11.8 (45.4–90.6) <0.001
AWO 31.2±37.8 (-39.9 to 98.9) 39.3±35.8 (-20.7 to 89.9) 33.2±15.7 (11.5−81.6) 0.75
RPEWR 18.4±40.0 (-103.3 to 63.9) 22.5±24.9 (-25.9 to 50.7) 31.2±9.8 (16.1–52.8) 0.31
Data are presented as mean ± standard deviation with ranges in parentheses.
The P values are for comparisons among basal cell adenoma, myoepithelioma, and Warthin tumor by using the 
analysis of variance test.
AE, attenuation value at early-phase CT; AD, attenuation value at delayed-phase CT; AWO, washout attenuation; 
RPEWR, relative percentage enhancement washout ratio.
Table 3. Comparison of CT parameters among groups
Basal cell adenoma vs. 
myoepithelioma
Basal cell adenoma vs. 
Warthin tumor
Myoepithelioma vs. 
Warthin tumor
AE 0.21 0.61 0.02
AD 0.07 0.12 <0.001
AWO 0.91 0.99 0.93
RPEWR 0.98 0.47 0.61
P values are for comparisons among basal cell adenoma, myoepithelioma, and Warthin tumor by using the post 
hoc Tukey test of the analysis of variance test (P < 0.05).
AE, attenuation value at early-phase CT; AD, attenuation value at delayed-phase CT; AWO, washout attenuation; 
RPEWR, relative percentage enhancement washout ratio.
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ratio of AWO to AE and is useful when the pre-
contrast CT scans are not available (23). In 
this study, although both AWO and RPEWR 
of MEs were greater than those of BCAs and 
WTs, the difference was not statistically sig-
nificant between the tumors. Our study also 
showed that both AE and AD were greater for 
MEs than for BCAs and WTs with statistically 
significant difference only being noted be-
tween MEs and WTs for both parameters. 
Although we have no clear explanation, we 
presume that the different histologic con-
stituents among the different tumors might 
partly account for it.
The washout enhancement pattern in 
these tumors might be attributed to hyper-
cellularity and the small volume of stroma 
as previously shown in the studies using 
dynamic CT and MRI (3, 25). The washout 
of contrast material depends on the dif-
ference in the amount of contrast material 
within the tumor between the intravascu-
lar and extravascular phases. Tumors with 
low cellularity and large extracellular space 
have a tendency to retain contrast materi-
al, resulting in a low washout ratio. In con-
trast, tumors with high cellularity and small 
extracellular space retain less contrast ma-
terial, resulting in a high washout ratio (3). 
On dynamic contrast-enhanced MRI, this 
washout pattern at two-phase CT, as seen in 
tumors with small extracellular space such 
as malignant lymphoma, can be a correlate 
to small Ve, the extravascular extracellular 
space volume fraction (26). 
Previous reports with multiple imaging 
modalities have attempted to correlate 
the imaging characteristics of the salivary 
gland tumors with the histopathologic fea-
tures. In their study on CT-histopathologic 
correlation for WTs, Woo et al. (13) reported 
that WTs had densely packed, capillary-like 
vessel networks with a high vascularity, 
which was presumed to be responsible for 
the cause of rapid contrast enhancement 
at early phase on two-phase CT scans. This 
correlates with a high microvessel count in 
the study by Yabuuchi et al. (3). Woo et al. 
(13) also reported that leaky blood vessels 
accounted for early washout of contrast 
material on two-phase CT scans. Similar to 
WTs, solid type BCAs were reported to have 
numerous endothelial-lined vascular chan-
nels with prominent small capillaries and 
venules (14, 16, 17, 21), accounting for early 
enhancement with subsequent washout 
(6, 21, 22). Likewise, MEs were reported to 
demonstrate epithelial nets with numerous 
blood vessels on histologic examination 
(18, 24). In their study with 10 MEs of the 
parotid gland, Wang et al. (18) reported that 
all tumors appeared as homogeneous or 
heterogeneous well enhancing nodules on 
postcontrast CT scans obtained at 40 s after 
the onset of contrast injection. Although 
the features of MEs on dynamic CT and MRI 
have seldom been reported, one case of ME 
included in the study by Yabuuchi et al. (3) 
demonstrated early enhancement and high 
washout on dynamic contrast-enhanced 
MRI, similar to WTs.
Although the majority of BCAs and MEs 
demonstrated the washout enhance-
ment pattern in this study, a small portion 
of BCAs (4/19, 21%) and MEs (3/12, 25%) 
showed gradual enhancement pattern on 
two-phase CT scans. The enhancement 
pattern other than the washout pattern 
has also been reported in cases of BCA and 
ME. As for BCAs, Lee et al. (21) reported that 
while the solid type showed early strong 
Figure 1. a, b. Boxplot (a) shows the distribution of the attenuation values of the solid component 
of the tumors at early and delayed phases. The thick horizontal line is the median (50th percentile) of 
the measured attenuation values, and the tops and bottoms of the boxes represent the 25th and 75th 
percentiles, respectively. Whiskers represent the range from the largest to smallest observed data 
sets within the 1.5 interquartile range presented by the box. Graph (b) shows the lines connecting 
mean attenuation values between the early and delayed phases on two-phase CT; washout pattern 
of enhancement is clearly shown in all three tumor groups.
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enhancement and a washout pattern like 
WTs, the tubular/trabecular type demon-
strated less strong early enhancement and 
the gradual enhancement pattern on two-
phase CT scans, as seen in PAs. In their two-
phase CT study by Joo et al. (20), all of six 
BCAs showed increased enhancement on 
delayed phase CT scans. The various pat-
tern of enhancement reported in the differ-
ent studies might be ascribed to histologic 
variations that consist of the individual tu-
mor. Likewise, MEs might also demonstrate 
the gradual enhancement pattern, if they 
contain a large area of collagenous or mu-
coid stroma (18, 24). Joo et al. (20) reported 
that while only one of three MEs showed 
decreased enhancement, the remaining 
two MEs showed increased enhancement 
on delayed phase CT scans. In their study 
with contrast-enhanced MRI, Ding et al. (19) 
reported that all five MEs exhibited early 
moderate to marked enhancement on the 
axial images, followed by prolonged en-
hancement on the consecutive coronal im-
ages. Their results are apparently in contrast 
to ours. The difference in the results might 
be related to the concept of prolonged en-
hancement used in their study. They neither 
defined the term clearly nor provided the 
numeric data of the degree of enhance-
ment objectively. Through the figures in 
their article, we presume that they might 
have used prolonged enhancement when 
the tumor demonstrated enhancement at 
delayed phase, irrespective of washout or 
gradual enhancement pattern.
The clinical implications of this study 
may not be great, because the treatment 
would not be changed, no matter what di-
agnoses are made. In general, identification 
of the histology of various benign tumors 
on preoperative imaging studies would be 
less important than differentiation between 
benign and malignant tumors. However, 
from the radiologist’s standpoint, every trial 
should be done to recognize the histologic 
nature of the lesions during imaging evalua-
tion, because the biologic behavior, such as 
malignant potential and propensity to recur, 
may be different among the various benign 
tumors. For example, the malignant poten-
tial has been estimated as 9.5% of PAs after 
15 years, less than 1% of WTs, about 4% of 
BCAs, and up to 10% of MEs (8, 15, 18, 27).
Radiation exposure is an important issue 
of two-phase CT, which inevitably delivers 
a greater amount of radiation, compared 
with conventional single-phase CT. In 
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Figure 2. a, b. Basal cell adenoma of the right parotid gland in a 71-year-old woman. A well-defined 
ovoid mass (arrow) is located in the superficial lobe of the right parotid gland on two-phase CT 
scans. The mass shows marked contrast enhancement at early phase (a) and homogeneous washout 
of contrast material at delayed phase (b). The measured AE and AD are 116 and 87.7, respectively, 
resulting in AWO of 28.3 and RPEWR of 24.4%.
a b
Figure 3. a, b. Myoepithelioma of the left parotid gland in a 49-year-old woman. A well-defined 
ovoid mass (arrows) is seen in the superficial lobe of the left parotid gland on two-phase CT 
scans. The mass is composed of a large solid component laterally and a smaller cystic component 
medially, the latter of which demonstrates marked homogeneous contrast enhancement at early 
phase (a) and homogeneous washout of contrast material at delayed phase (b). The measured AE 
and AD of the solid component of the tumor are 122.6 and 96.3, respectively, resulting in AWO of 
26.3 and RPEWR of 21.5%. 
a b
Figure 4. a, b. Warthin tumor of the right parotid gland in a 50-year-old man. A well-defined ovoid 
mass (arrow) is seen in the superficial lobe of the right parotid gland on two-phase CT scans. The mass 
shows marked homogeneous contrast enhancement at early phase (a) and homogeneous washout of 
contrast material at delayed phase (b). The measured AE and AD are 121 and 90, respectively, resulting in 
AWO of 31 and RPEWR of 25.6%.
a b
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the present study, the measured CTDIvol 
ranged from 10.9 to 37.52 mGy per phase, 
which was comparable to the reported 
CTDIvol in neck volume CT (2, 3). The 
scheme to reduce the radiation dose such 
as automatic tube current modulation tech-
nique is always recommended during two-
phase CT (28).
This study had several limitations. First, 
we did not perform the radiologic-patho-
logic correlation of the individual tumor, 
which might have explained the differ-
ences of the attenuation characteristics 
among tumors, such as AE and AD. Second, 
among the various types of benign parotid 
tumors, we only selected BCAs and MEs to 
compare their enhancement pattern with 
that of WTs. Other less common benign tu-
mors such as oncocytomas may manifest 
as a mass with the same enhancement pat-
tern as WTs. We expect further validation 
with a large cohort of various benign tu-
mors. Third, we did not obtain precontrast 
CT scans which are essential to know the 
actual increment of the attenuation values 
on postcontrast CT scans. This inevitably 
hindered us from analyzing the full range 
of enhancement pattern of the tumors on 
two-phase CT scans. 
In conclusion, BCAs and MEs of the parot-
id gland demonstrated early enhancement 
and a washout pattern on two-phase CT 
scans, which is regarded as the characteris-
tic features of WTs. The pattern of enhance-
ment seen in these tumors seems to reflect 
the prominent vasculature within the solid 
component of the tumors histologically. We 
suggest that in addition to WTs, BCAs and 
MEs might be included in the list of differ-
ential diagnosis, when the parotid tumors 
show early enhancement and a washout 
pattern on two-phase CT scans. 
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